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Syncytium-inducing (SI) variants of human immunodeficiency virus type 1 (HIV-1) are evolutionary variants
that are associated with rapid CD41 cell loss and rapid disease progression. The heteroduplex tracking assay
(HTA) was used to detect evolutionary V3 variants by amplifying the V3 sequences from viral RNA derived from
50 samples of patient plasma. For this V3-specific HTA (V3-HTA), heteroduplexes were formed between the
patient V3 sequences and a probe with the subtype B consensus V3 sequence. Evolution was then measured by
divergence from the consensus. The presence of evolutionary variants was correlated with SI detection data on
the same samples from the MT-2 cell culture assay. Evolutionary variants were correlated with the SI
phenotype in 88% of the samples, and 96% of the SI samples contained evolutionary variants. In most cases
the evolutionary V3 variants represented discrete clonal outgrowths of virus. Sequence analysis of the six
discordant samples that did not show this correlation indicated that three non-syncytium-inducing (NSI)
samples had V3 sequences that had evolved away from the consensus sequence but not toward an SI genotype.
A fourth sample showed little evolution away from the consensus but was SI, which indicates that not all SI
variants require basic substitutions in V3. The other two samples had SI-like genotypes and NSI phenotypes,
suggesting that V3-HTA was able to detect SI emergence in these samples in the absence of their detection in
vitro. V3-HTA was also used to confirm SI variant selection in MT-2 cells and to examine the possibility of
variant selection during virus culture in peripheral blood cells.
The rapid evolution of human immunodeficiency virus type
1 (HIV-1) in infected individuals is due to high replication
rates (24, 49), error-prone replication (39), and selective pres-
sure exerted by the host’s immune system (33). Several types of
variants, which can be distinguished by their in vitro pheno-
types, can emerge over the course of infection. Syncytium-
inducing (SI) variants of HIV-1 are able to induce syncytium
formation in a transformed T-cell line called MT-2, and their
presence in peripheral blood mononuclear cells (PBMC) or
plasma has been correlated with rapid disease progression (28,
46). SI variants are only rarely transmitted; instead they evolve
de novo in 50% of infected individuals from a non-syncytium-
inducing (NSI), macrophage-tropic parent (45). When SI vari-
ants are transmitted, the onset of AIDS is very rapid, typically
within 2 years of infection (47). It is not known what role SI
variants play in rapid progression, although it has been sug-
gested that they may be more than bystanders, since the plasma
viral load increases after the emergence of SI variants (10). Not
all individuals who show rapid progression have SI variants,
however, which suggests that the SI phenotype in vitro does
not fully explain the phenomenon of rapid progression.
The SI phenotype is one of many traits along a continuum of
HIV-1 phenotypes. The SI phenotype is usually linked with
rapid replication rates to high titers, the ability to infect trans-
formed T-cell lines, and the loss of the ability to infect mac-
rophages (2). It is not known, however, whether all these char-
acteristics are conferred by the same determinants that give the
SI phenotype. Tropism is determined by the ability of the virus
to bind to both CD4 and a specific chemokine coreceptor.
CCR5 and CXCR4 are the chemokine receptors used most
commonly by HIV-1, with CCR5 usage associated with mac-
rophage-tropic viruses and CXCR4 usage associated with T-
cell-line-tropic viruses (15, 18, 19). Many primary SI viruses
have been found to be dual tropic, in that they can infect both
macrophages and transformed T-cell lines. As expected, dual-
tropic viruses are able to use either receptor for infection, and
some of the viruses can use other chemokine receptors as
coreceptors (9, 17, 44). However, coreceptor usage does not
completely define tropism. Cheng-Mayer et al. and others were
unable to show a strict correlation between macrophage tro-
pism and usage of the CCR5 coreceptor (5, 16). The linkage
between tropism and phenotype is also unclear. Because a
transformed T-cell line is used to test for the SI phenotype, SI
variants must be either T-cell line tropic or dual tropic. But the
NSI phenotype does not predict tropism, since Chesebro et al.
found that there are separate determinants for NSI phenotype
and macrophage tropism (8). Schuitemaker et al. described
five different viral classifications based on isolates from differ-
ent time points of infection that had different tropisms and NSI
or SI phenotypes (42). Given that the cell type supporting
replication in vivo is not known, the meaning of these in vitro
correlates of phenotype remains uncertain.
Studies of the SI phenotype have focused on the determi-
nants required to switch from NSI to SI. All of the determi-
nants for NSI or SI phenotype and tropism are in the env gene,
with most of them in the third variable (V3) domain of gp120.
V3 contains the primary neutralization epitope of gp120 (27)
and is, therefore, under high selective pressure from the im-
mune system. Recombinant and mutagenesis studies of sub-
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type B viruses have identified many different amino acid sub-
stitutions that can contribute both to the SI phenotype and to
a switch in tropism, although none of the changes is found in
all SI variants (6–8, 11, 22, 25, 38, 43, 50). An accumulation of
basic amino acids in the V3 domain, especially at positions 11,
24, 25, and 32, is the most common feature of SI variants (21,
34). Also, the V3 regions of SI variants have approximately
twice as much variation (beyond the basic amino acid substi-
tutions) as NSI V3 regions compared to a consensus sequence
(7, 34).
The heteroduplex mobility assay (HMA) and the heterodu-
plex tracking assay (HTA) were developed to examine the
divergence in HIV env sequences within individuals and be-
tween populations by using PCR products that included V3
(13, 14). The assays are based on the observation that DNA
heteroduplexes migrate through polyacrylamide more slowly
than do DNA homoduplexes due to kinks formed by the un-
paired bases (3). HMA examines all of the heteroduplexes
formed by analysis of ethidium bromide-stained gels, while
HTA is used to visualize only the heteroduplexes that form
between a radioactively labeled probe and the driver PCR
products. By using nested PCR to amplify a 700-bp region
including V3, Delwart et al. showed that the complexity of viral
variants in PBMC DNA from an infected individual could be
visualized by HMA (13). Shifts in mobility were shown to
depend on the extent of divergence between the two strands of
the heteroduplex: the greater the divergence, the slower the
migration of the heteroduplex.
In this report we describe a rapid genotype-based assay for
the detection of evolutionary variants of V3. The assay involves
the amplification of V3 sequences from viral RNA isolated
from patient plasma, followed by analysis of the V3 sequences
by HTA to determine whether evolutionary variants are
present in the patient plasma sample. The heteroduplex pat-
terns were found to be reproducible and represented the se-
quence variants in the plasma samples. The V3 sequences from
50 patients were analyzed by using V3-specific HTA (V3-
HTA), and the results were compared with the NSI or SI
phenotype determined in MT-2 cell culture. V3-HTA was able
to detect 96% of MT-2 cell-tropic, SI variants as evolutionary
V3 variants and overall showed an 88% correspondence in
identifying SI and NSI viruses. Further examination of the
viruses that were discordant between the MT-2 cell culture
assay and V3-HTA has revealed novel HIV-1 variants, with an
example of an SI virus without basic substitutions in V3 and
two NSI viruses with basic substitutions usually associated with
the SI phenotype. In addition, V3-HTA has been used to
document the selection of SI variants in MT-2 cells and to
show the potential for selection during culture of virus in
peripheral blood cells.
MATERIALS AND METHODS
Patient samples. All samples used in this study were obtained as excess tissue
samples with institutional review board approval. Blood samples were collected
from the patients through the AIDS Clinical Trial Units at the University of
North Carolina at Chapel Hill, Duke University, and Georgetown University or
from patients attending the Infectious Disease Clinic at the University of North
Carolina at Chapel Hill.
Cells, plasma, and virus culture. Blood from patients was collected in acid-
citrate-dextrose tubes. After centrifugation at 800 3 g for 20 min, cell-free
plasma was aliquoted and frozen at 270°C. PBMC were isolated on Ficoll-
Hypaque gradients and cocultured with phytohemagglutinin-stimulated PBMC
from uninfected donors in quantitative HIV cultures as described previously (20,
37). Excess PBMC were frozen as viable cells in freezing medium containing
dimethyl sulfoxide as described previously (37). After 2 weeks in culture, virus
from the cocultures was tested in triplicate for syncytium formation in MT-2 cells
by using a previously described method (26, 37). Virus isolates from each positive
PBMC culture were stored at 270°C. In a few cases these frozen virus stocks
were used to confirm the presence or absence of SI isolates in MT-2 cell cultures.
Supernatants from some of these MT-2 and PBMC cultures were also tested by
V3-HTA.
Plasmids and vectors used. Plasmid pUC112-1, a SacI subclone of JR-FL, was
generously provided by Irvin Chen, University of California, Los Angeles (29).
The NL4-3 V3 sequence was amplified from a subclone of the NL4-3 genomic
molecular clone (1). Plasmids B-NSI and B-SI are clones generated from a PCR
product from PBMC genomic DNA derived from patient B, described by Milich
et al. (34); the PCR products were cloned into the pCRII TA vector (Invitrogen).
The JR-FL probe plasmid pJN27 was made by cloning the 141-bp V3 PCR
product from pUC112-1 into pCRII. The downstream EcoRI site was destroyed
by partially digesting the plasmid with EcoRI, filling in the overhangs with the
Klenow fragment of DNA polymerase I, and recircularizing the plasmid. Reverse
transcription (RT)-PCR products were cloned into the pT7Blue TA vector
(Novagen). After transformation of the ligations into DH5a bacteria, the white
colonies were screened by colony PCR (31) followed by HTA as described below.
Plasmids were sequenced by using Sequenase 2.0 (U.S. Biochemicals). Se-
quences were manipulated with Wisconsin Package version 9.0 (Genetics Com-
puter Group, Madison, Wis.).
RNA isolation and RT-PCR. Thawed plasma or supernatant (0.5 to 1.0 ml)
from PBMC coculture was spun in a Beckman TL-100 ultracentrifuge with a
TL-55S rotor at 45,000 rpm for 15 min. The virus pellet was resuspended in 140
ml of plasma or phosphate-buffered saline. Supernatant from MT-2 cells was
used without centrifugation. Viral RNA was isolated from the 140 ml of virus by
using a QIAamp Viral RNA kit (Qiagen), which gave a final volume of approx-
imately 50 ml. Primers for RT-PCR were 59-GAATCTGTAGAAATTAATTGT
ACAAGACCC-39 (V3L4) and 59-TTTTGCTCTACTAATGTTACAATGTGC
TTG-39 (V3R5). RT-PCR was performed as follows. Ten-microliter RT reac-
tions consisted of 5 ml of viral RNA, 13 Perkin-Elmer PCR buffer II (50 mM
KCl, 10 mM Tris [pH 8.3]), 5 mM MgCl2, 1 mM each deoxynucleoside triphos-
phate (dNTP) (U.S. Biochemicals), 15 pmol of primer V3R5, 10 U of RNase
inhibitor (Perkin-Elmer Corp.), and 25 U of Moloney murine leukemia virus
reverse transcriptase (Perkin-Elmer). RT was done at 42°C for 30 min, followed
by 10 min at 99°C to inactivate the reverse transcriptase. Forty microliters of
PCR master mix (13 PCR buffer II, 2.5 mM MgCl2, 15 pmol of primer V3L4,
1.25 U of Perkin-Elmer AmpliTaq polymerase) was then added to the RT
reaction mixtures. PCR was carried out in either a Perkin-Elmer TC1 thermal
cycler (95°C for 3 min; 95°C for 10 s, 48°C for 10 s, 72°C for 20 s, 40 cycles) or
a Stratagene Gradient-40 Robocycler (96°C for 3 min; 96°C for 45 s, 51°C for
45 s, 72°C for 45 s, 40 cycles). PCRs with plasmids were done by using the same
cycle conditions with the following reaction components: 13 PCR buffer II, 2.5
mM MgCl2, 0.1 mM each primer, 10 pg of plasmid, and 1.25 U of AmpliTaq
polymerase. RT-PCR amplifications were repeated for higher efficiency of am-
plification with Boehringer Mannheim enzymes in a method modified from their
Titan one-tube RT-PCR system. Twenty-microliter RT reaction mixtures con-
sisted of 1 to 5 ml of viral RNA, 13 Titan RT-PCR buffer, 2.5 mM MgCl2, 5 mM
dithiothreitol, 0.5 mM each dNTP, 15 pmol of primer V3R5, 10 U of RNase
inhibitor (Perkin-Elmer), and 12 U of avian myeloblastosis virus reverse tran-
scriptase (Boehringer Mannheim). RT was done at 42°C for 30 min, and the
enzyme was inactivated at 99°C for 2 min. Thirty microliters of PCR mix (13
RT-PCR buffer, 2.5 mM MgCl2, 5 mM dithiothreitol, 15 pmol of primer V3L4,
and 2.6 U of Expand High Fidelity enzyme mix [Boehringer Mannheim]) was
then added to the RT reaction mixtures. PCR was done in the Stratagene
Robocycler with the following program: 95°C for 2 min 45 s; 95°C for 45 s, 51°C
for 45 s, 68°C for 1 min, 40 cycles (after the first 10 cycles, 1 min was added to
the 68°C step for 10 cycles, 2 min was added for the next 10 cycles, and 3 min was
added for the last 10 cycles). PCR products were sequenced by using the ABI
PRISM dye terminator cycle sequencing kit (Perkin-Elmer).
HTA. The JR-FL V3 probe was labeled by first digesting 1.5 mg of plasmid
pJN27 with EcoRI. A total of 1.25 mCi of a-35S-dATP (1,250 Ci/mmol; NEN Life
Science Products) and 2 U of the Klenow fragment of DNA polymerase I were
added to the digest for 15 min, followed by heat inactivation of the enzymes. The
plasmid was further digested with PstI to remove the probe from the vector, and
the probe was then purified by using QIAquick PCR purification columns (Qia-
gen) to give a final volume of 50 ml. Heteroduplex formation reactions were done
as described by Delwart et al. (14) with the following modifications. The reac-
tions consisted of 1 ml of 103 annealing buffer (1 M NaCl, 100 mM Tris-HCl [pH
7.5], 20 mM EDTA), 8 ml of unpurified PCR product, 0.1 mM primer V3L4, and
labeled JR-FL probe to make 10 ml. Primer V3L4 was included in the hetero-
duplex formation reactions to normalize for PCRs containing excess primer after
amplification. The reactions were denatured at 95°C for 2 min and allowed to
anneal at room temperature for 5 min. The heteroduplexes were separated in
12% acrylamide (37.5:1, acrylamide:bisacrylamide) gels in 13 TBE buffer (41). A
model V16-2 vertical gel apparatus (Gibco BRL) was used, and the gels were run
at 17 mA (per gel) until the xylene cyanol dye had run off the bottom of the gel
(approximately 6 h). The gels were dried and analyzed by using either autora-
diography with X-ray film or phosphor imaging screens (Molecular Dynamics).
Nucleotide sequence accession numbers. The V3 nucleotide sequences re-
ported here have been assigned GenBank accession no. AF001798 to AF001827.
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RESULTS
SI and NSI sequences can be distinguished by an HTA
directed to the V3 coding region. HTA is able to distinguish
between heteroduplexes based on the number of mismatches
between the probe sequence and the test sequence (13). Be-
cause the changes in the V3 coding region of HIV-1 env that
lead to the SI phenotype differ widely among isolates, HTA is
ideal for SI detection. Previous applications of HTA employed
PCR products between 350 and 1,200 bp, typically spanning
sequences from V3 to V5 (12, 14). Because the difference in
variability that distinguishes SI and NSI variants is largely
confined to V3, we designed two 30-nucleotide primers to
amplify a 141-bp PCR product, of which 81 bp are target
dependent and within V3. The V3 sequence from the mac-
rophage-tropic NSI molecular clone JR-FL was chosen for use
as the probe in the heteroduplex reactions because it is nearly
identical to the consensus sequence for subtype B (36). SI
sequences on average have twice as much variation in sequence
from the consensus as do NSI sequences, in addition to the
accumulation of basic amino acid substitutions (34). There-
fore, this probe should be different from most SI sequences
and more similar to most NSI sequences in patients infected
with subtype B HIV-1, making the SI heteroduplexes distin-
guishable from the NSI heteroduplexes. The probe was con-
structed by amplifying the 141-bp region from the pUC112-1
molecular clone of JR-FL (29) and ligating the PCR product
into a TA vector. By using a cloned fragment rather than
labeling during PCR, greater consistency in probe preparation
was achieved. A second probe-containing plasmid was made by
eliminating one of the EcoRI sites flanking the insert to allow
radioactive end labeling of only one strand by filling in the
remaining EcoRI overhang with a labeled nucleotide (Fig. 1A).
In order to test our ability to differentiate between homo-
geneous NSI and SI sequences by using the JR-FL V3 probe
and V3-HTA, V3 region sequences were amplified from mo-
lecular clones of known sequence. These clones included
JR-FL (control) and NL4-3 (SI) subclones and two clones
(B-NSI and B-SI) generated from a patient whose lymphocytes
harbored both NSI- and SI-like V3 sequences (34). Figure 1B
shows a comparison of the sequences of the clones used. The
PCR product from each clone was mixed with probe labeled on
one or both strands, denatured, and annealed to form hetero-
duplexes. The heteroduplexes were separated in a polyacryl-
amide gel, producing sample-specific migration patterns. Gels
containing 12% acrylamide produced the optimal distinction
between the two types of sequences, and probes labeled on
only one strand produced the clearest patterns for interpreta-
tion. Adding denaturant (15% urea [12]) to the gel caused
smearing of some of the slower-migrating SI bands, which
made the bands less prominent. The probe labeled on both
strands usually formed twice the number of distinct heterodu-
plex species as the probe labeled on just one strand, since the
two strand-specific heteroduplexes that form with each product
usually migrate differently (not shown). Figure 1C shows the
mobility patterns of the PCR products annealed with the probe
labeled on one strand. The single-stranded probe and the dou-
ble-stranded probe homoduplex are both seen in all lanes. The
bands at the top of the gel are labeled vector fragments. All
heteroduplexes formed between the probe and PCR products
run more slowly (i.e., are higher in the gel) than the probe
homoduplex, even when the PCR product is from JR-FL; this
is because the probe has short extensions on both ends derived
from the plasmid. This slightly greater length produces tails on
each of the heteroduplexes that slow their mobility in poly-
acrylamide slightly. Therefore, any bands that are above the
probe homoduplex band are scored as heteroduplexes in this
assay.
The NSI and SI heteroduplexes migrated very differently,
demonstrating that V3-HTA can distinguish these NSI and SI
sequences. The JR-FL and B-NSI sequences produced hetero-
duplexes with fast mobility (close to the probe homoduplex),
while the NL4-3 and B-SI sequence heteroduplexes were much
slower, with the NL4-3 heteroduplex close to the single-
stranded probe band. The NL4-3 sequence has fewer mis-
matches with the JR-FL sequence than does B-SI, but it has a
6-bp insertion as well as a 3-bp deletion. These types of
changes have large effects on the mobility of the heterodu-
plexes (48). The B-NSI heteroduplex shows that an NSI se-
quence with five differences in sequence from JR-FL (within
the target-dependent 81 bp) still migrates like an NSI sequence
and is distinguishable from the B-SI sequence. Thus, the assay
does not measure total variability but rather distinctive fea-
tures of V3 sequence evolution associated with the SI pheno-
type (see below).
FIG. 1. (A) Probe for SI detection by V3-HTA. The V3 region PCR product (shown in capital letters) from the pUC112-1 subclone of JR-FL was cloned into the
pCRII TA vector. The primers (described in Materials and Methods) that were used to amplify V3 from plasmids and viral RNA are underlined. The EcoRI and PstI
sites were used to excise the probe from the vector. The V3 coding region is shown in bold; lowercase letters indicate additional sequences derived from the vector
that are part of the probe. (B) V3 sequence alignment of the clones used for V3-HTA. JR-FL and B-NSI are NSI-like; NL4-3 and B-SI are SI-like. The amino acids
of V3 are numbered starting with the first cysteine of V3 as 1. All sequences are compared with JR-FL; dashes represent the same nucleotide as in the JR-FL sequence,
while dots represent deletions. (C) Autoradiogram of V3-HTA gel. The arrows designate the single-stranded probe (top) and the probe homoduplex (bottom). The
lane labeled “probe” contains only probe in a heteroduplex reaction.
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Comparison between V3-HTA and the MT-2 cell culture
assay for SI detection. In order to test the effectiveness of
V3-HTA in detecting SI variants in patients, plasma samples
from 50 patients were tested by V3-HTA. The detection of
evolutionary variants by V3-HTA was compared with the phe-
notypes determined by the MT-2 cell culture assay as a mea-
sure of V3-HTA efficiency. The MT-2 cell culture assay used
virus generated by coculture of the patients’ infected PBMC
with phytohemagglutinin-stimulated PBMC from uninfected
donors. The infected PBMC were taken from the same blood
samples as the plasma used for V3-HTA. Plasma samples were
chosen so that about half of the samples were from patients
harboring SI variants as measured by the MT-2 cell culture
assay.
Viral RNA was isolated from the plasma, and RT-PCR was
performed to generate V3 PCR products for V3-HTA. Figure
2A shows representative results from the V3-HTA gels. Het-
eroduplex patterns are shown for four NSI plasma samples that
did not have V3 evolutionary variants and four SI plasma
samples that had V3 evolutionary variants. The latter lanes
show examples of the variety of heteroduplex patterns seen in
SI plasma samples. The heteroduplex patterns showed a sur-
prising degree of homogeneity in the viral pools, even among
many of the patient plasma samples with SI variants. As the
representative heteroduplex patterns in Fig. 2A show, the pa-
tient plasma samples with V3 evolutionary variants can have
greater complexity (more bands) overall than those without,
but most of these samples had only one or two major variants.
This analysis confirms earlier observations, based on PBMC
DNA, that viral outgrowths are largely clonal (30, 34). The
V3-HTA results also agree with the observation that viral se-
quences tend to be more homogeneous early in infection and
more heterogeneous late in infection (32). The variability that
is seen among patients suggests that V3-HTA is a sensitive
assay for genotypic differences among the SI variants that
evolve independently in each individual.
In an attempt to assess whether the V3-HTA patterns were
reproducible, several of the patient plasma samples that had
multiple bands in the V3-HTA were amplified in triplicate and
V3-HTA was done on all of the products. The same patterns
were obtained with all products from a single RNA sample,
some of which are shown in Fig. 2B. In addition, consecutive
plasma samples (within 2 months) were obtained from a few of
the patients. The V3-HTA patterns of these later plasma sam-
ples were the same in heteroduplex pattern and intensity (not
shown), indicating that the V3 sequence heteroduplex patterns
were reproducible and were representative of the sequences in
the patients’ blood at the time of collection. These results are
in agreement with the reproducibility of HTA patterns seen by
Delwart et al. (13), who showed that their patterns were re-
producible when there was high DNA input in their first round
of nested PCR. Since we were not using nested PCR on these
viral RNA samples, our reproducibility results show that we
were using a sufficient amount of input RNA to get proper
sampling of the variants present. We have not yet established
limits on the reproducibility of the assay under conditions of
low virus load.
The mobility of the slowest (highest in the gel) heteroduplex
for each of the 50 patient plasma samples was measured (dis-
tance from the well in centimeters) and divided by the mobility
of the probe homoduplex to produce a heteroduplex mobility
ratio that was compared among samples. The heteroduplex
mobility ratios are shown graphically with the MT-2 cell cul-
ture phenotypes in Fig. 3. The V3-HTA results were optimally
grouped by drawing a line at 0.91 to separate the majority of
the NSI and SI samples. Samples above the line had V3 evo-
lutionary variants, and samples below the line did not. Because
of the small sample size in this study, the line may be subject to
a small change as the assay continues to be tested. Of the 27
patient plasma samples that had the SI phenotype in MT-2
cells, 26 had V3 evolutionary variants that formed heterodu-
plexes with mobility ratios of less than 0.91, while 18 of the 23
MT-2 NSI samples did not. This is an overall concordance of
88% (with 6 of 50 samples discordant between the two assays)
and 96% concordance in identifying SI patient samples by
detection of V3 evolutionary variants in plasma virus.
The majority of V3 variants present in a patient’s plasma
are detected by V3-HTA. It is possible that V3-HTA does not
show the correct heteroduplex pattern for a patient’s viral pool
if the majority of variants in a patient’s blood are diverse and
each is at low abundance. This possibility was tested by ana-
lyzing individual clones of the PCR products from each of two
patient plasma samples, 300 and 717. The V3-HTA patterns
for these plasma samples are shown in Fig. 4A. The clones
were sequenced (Fig. 5A) and analyzed by V3-HTA beside the
patient plasma PCR product (not shown) to connect each
sequence with a specific heteroduplex band from the patient
plasma sample; heteroduplex bands were numbered starting
from those closest to the top of the gel.
FIG. 2. (A) Examples of V3-HTA patterns for 8 of the 50 patient plasma
samples. The NSI and SI designations refer to the phenotypes determined by
MT-2 cell culture assay. (B) V3-HTA of duplicate, independent RT-PCRs for
each RNA sample. Only the bottom halves of the gels are shown; for descriptions
of the top and bottom bands in each lane, see the legend to Fig. 1.
FIG. 3. Mobility ratios determined from V3-HTA were plotted with the
MT-2 cell phenotype for each of the 50 patient plasma samples tested. Mobility
ratios were calculated by dividing the migration distance of the top heteroduplex
by the migration distance of the probe homoduplex. The dashed line at 0.91
designates the maximum mobility ratio for a positive score for the presence of V3
evolutionary variants. For comparison, the mobility ratio for the JR-FL control
PCR product was 0.96.
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All of the clones analyzed matched in mobility one of the
bands from the patient plasma sample RNA, indicating that
the heteroduplex patterns accurately displayed the variants
present in the plasma. The 38 clones from patient plasma
sample 300 included 18 with the same NSI-like sequence that
had the mobility of the darkest band in the V3-HTA (Fig. 4A,
band 4). Several other clones had similar sequences and the
same mobility. There were nine clones corresponding to band
2, which represented the major SI-like variant in this individ-
ual, while bands 1 and 3 were represented by one and three
clones, respectively. Similar results were obtained with patient
sample 717. The percentage of clones corresponding to each
band is shown in Table 1, as is the relative percentage by
intensity of each of the bands on the V3-HTA gel. The per-
centages are similar, indicating that clone screening is consis-
tent with the pattern of variants as detected by V3-HTA. The
discrepancies in absolute values between the numbers are
likely due to the small numbers of clones examined.
For patient plasma sample 300, the clone from band 1 had
only one more substitution than the clones from band 2, while
many of the clones in band 4 differed by a single substitution
without a shift in mobility. Also, two clones from sample 300
with six substitutions each had different mobilities (bands 3 and
4). These results show that HTA does not differentiate hetero-
duplexes solely by the number of mismatches. We have con-
cluded, therefore, that V3-HTA is more sensitive to mismatch
clustering than to the total number of mismatches.
Patient plasma samples with discordant phenotypes identi-
fied differences between V3-HTA and the MT-2 cell culture
assay. The six patient plasma samples with discordant pheno-
types were examined further to determine why they did not
show a correlation between SI phenotype and the presence of
V3 evolutionary variants. Figure 4B shows the heteroduplex
patterns for the discordant patient samples. To ensure that the
patient PBMC were not misscored for syncytium formation in
the initial MT-2 cell culture assay, the discordant samples were
FIG. 4. (A) V3-HTA of patient plasma samples 300 and 717. The positions
of the heteroduplexes generated with each patient sample are shown and num-
bered starting with the most slowly migrating species. (B) V3-HTA of the six
discordant patient plasma samples that did not show a correlation between MT-2
cell phenotype and detection of V3 evolutionary variants by V3-HTA.
FIG. 5. (A) V3 sequence alignment of individual clones of variants from patient plasma samples 300 and 717. In both groups, the sequences are compared with the
sequence of JR-FL to highlight mismatches in heteroduplexes. Dashes represent the same nucleotide as shown in the JR-FL sequence. The number of clones isolated
with the given sequence is shown, as is the mobility of each sequence as determined by V3-HTA. Heteroduplex bands shown in Fig. 4 were numbered from the top.
(B) V3 nucleotide and predicted amino acid sequence alignment of the variants from the six discordant patient plasma samples. The numbering of V3 begins with the
first cysteine as amino acid 1. Only predicted amino acids that differ from JR-FL are shown; dots represent deletions.
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retested from frozen viral isolates obtained from the initial
coculture. In all cases, the phenotype of the PBMC coculture
virus was confirmed.
The RT-PCR products from two discordant samples with
homogeneous PCR products were sequenced using an auto-
mated sequencing machine. Patient samples 119 and 252,
which had V3 evolutionary variants but did not cause syncytia
in MT-2 cells, each had a 3-bp deletion in the V3 sequence that
caused the heteroduplex shift (Fig. 5B). Thus, these sequences
have NSI-like genotypes and NSI phenotypes, with a small
deletion that indicates V3 evolution by V3-HTA. In these
cases, direct sequence analysis of the homogeneously shifted
PCR products explained the discordance between V3-HTA
and the MT-2 assay. Therefore, discordance between the as-
says can be reduced in future applications by sequencing all
homogeneous PCR products that have heteroduplex shifts to
discover whether there are deletions or insertions.
Three clones of the RT-PCR product from patient plasma
sample 349, which did not have V3 evolutionary variants but
induced syncytia in MT-2 cells, encoded no basic amino acid
substitutions in their V3 regions, although each one did encode
a substitution to glycine at position 25. To verify that this
variant was responsible for the SI phenotype, viral RNA was
isolated from the medium supernatants of the PBMC cocul-
ture and MT-2 cell infection of patient sample 349. RT-PCR
was performed on the viral RNA, and the heteroduplex pat-
terns were compared with the pattern from the plasma sample.
In the PBMC coculture and MT-2 cell supernatants, just as in
the plasma, only the single fast-migrating heteroduplex was pres-
ent. The sequence of the RT-PCR product from the MT-2 cell
supernatant was the same as the sequence of the plasma RT-
PCR product, indicating that this variant is able to induce syn-
cytia in vitro despite a lack of SI-associated amino acid substi-
tutions within V3.
For discordant patient samples that had heterogeneous viral
pools and therefore could not be sequenced directly from the
PCR product, the PCR products were cloned and then
screened by V3-HTA to identify clones that had the same
mobility as the sequences of interest. The sequences of these
clones are shown in Fig. 5B. Patient samples 115, 129, and 216
had V3 evolutionary variants but did not induce syncytia in
MT-2 cells. The sequences of the two heteroduplex variants
from patient plasma sample 115 show that there is only a
one-nucleotide difference between them despite a large mobil-
ity shift. Both variants had many substitutions, although none
of the substitutions are associated with the SI phenotype. The
added nucleotide substitution in the top variant produced a
cluster of mismatches with the JR-FL probe, causing the shift
in mobility of this variant heteroduplex. The sequences of the
top heteroduplexes from patient plasma samples 129 and 216
showed that these variants had several SI-associated substitu-
tions, including basic substitutions in both cases. However,
these changes are apparently insufficient for syncytium induc-
tion in MT-2 cells. Longitudinal studies of patients are re-
quired to determine if sequence variants like these represent
precursors to SI variants, pathogenic variants that do not in-
duce syncytia in MT-2 cells, or NSI variants.
Analysis of the variants produced by PBMC coculture and
MT-2 cell infection and comparison to variants present in
plasma. In our comparison of V3-HTA of plasma RNA to the
MT-2 cell culture assay for the ability to detect SI variants, the
two assays could be detecting completely different virus pop-
ulations. It is not known where in the body SI and NSI viruses
are produced, so the virus in the plasma could be unrelated to
the virus produced by coculture of patient PBMC. Also, selec-
tion may occur for certain variants during PBMC coculture and
minor variants could be selected in the subsequent MT-2 cell
infection. Selection of sequence variants has been previously
shown to occur during culture of PBMC from some patients
(40). In that study, viral tat and env sequences were compared
among plasma, uncultured PBMC DNA, and virus that grew
out of cultured PBMC, demonstrating that PBMC culture
sometimes produced only subsets of the sequences present in
the plasma or uncultured PBMC. V3-HTA is a convenient way
to address the question of selection in PBMC and MT-2 cells
by comparing the virus populations in these cells with the virus
population in plasma.
Supernatants containing cell-free virus from PBMC cocul-
ture and MT-2 cell infections were collected for 15 patient
samples that were SI in MT-2 cell culture. The heteroduplexes
corresponding to plasma, PBMC coculture, and MT-2 cell in-
fection from the same patient sample were compared by V3-
HTA, and three different types of heteroduplex patterns were
observed. The first type, seen in patient samples 622 and 476
(Fig. 6), had the same heteroduplex pattern from all viral
sources. This type was observed for three other patient sam-
ples. Only one heteroduplex was seen for patient sample 622,
indicating that the plasma variant detected by V3-HTA was the
variant that caused syncytia in MT-2 cells. Patient sample 476
had two heteroduplexes, indicating that both variants were
TABLE 1. Percentages of variants with specific mobilities from
cloned RT-PCR products and relative intensities
of heteroduplex bands in V3-HTA
Gel banda % Clones with samemobilityb









a Heteroduplex gel bands are numbered from the top.
b Percentage of clones that had the same mobility as the corresponding HTA
gel band. Thirty-eight clones were sequenced from patient sample 300, and
seventeen clones were sequenced from patient sample 717.
c Percentage by intensity for each band in V3-HTA as calculated by area
integration with ImageQuant software (Molecular Dynamics).
FIG. 6. V3-HTA comparison of variants present in plasma (P), PBMC co-
culture medium (C), and MT-2 cell medium (M), all derived from the same
patient blood samples (shown above the lanes).
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able to infect MT-2 cells and that at least one of them was able
to induce syncytia.
In the second type of heteroduplex pattern, several variants
were detected but selection in MT-2 cells was apparent. One of
the variants in plasma and PBMC coculture from patient sam-
ple 571 was not present in the virus from MT-2 cells. For
patient sample 264 (Fig. 6) and five others (not shown), the
same variants were detected in plasma and PBMC coculture
but the relative abundance of the variants was different be-
tween plasma and PBMC coculture. In the case of patient
sample 264, the higher variant that was more abundant in the
PBMC coculture was the one that induced syncytia. Therefore,
this variant was SI, fast replicating, and different from the
subtype B V3 consensus sequence while the lower variant was
NSI and slow replicating.
The third type of heteroduplex pattern had a difference
between the number of variants detected from plasma and that
detected from PBMC coculture. This type was seen for patient
sample 165 (Fig. 6) and two others (not shown). In the case of
patient sample 165, the plasma had an additional lower het-
eroduplex that would be scored as NSI by V3-HTA. Because
this variant did not appear in PBMC coculture, selection may
have occurred there. Alternatively, the change in pattern could
have been due to the lack of the lower heteroduplex variant in
the PBMC if it was produced by noncirculating cells, such as
macrophages or tissue lymphocytes. From these results, we
conclude that in most cases, V3-HTA identifies the same vari-
ants that emerge from PBMC coculture for MT-2 cell test
infection. For some samples, however, the variants that grow
out of PBMC coculture are only a subset of the variants found
in the plasma.
DISCUSSION
V3-HTA is a rapid genotype-based assay that is able to
detect evolutionary V3 variants of HIV-1 in samples of patient
plasma. In an analysis by V3-HTA of 50 plasma samples from
patients, 31 contained evolutionary V3 variants. The associa-
tion between the presence of evolutionary variants and SI
variants in patient samples was determined by comparing the
results of V3-HTA with the SI or NSI phenotypes from the
MT-2 cell culture assay. V3-HTA indicated the presence of
evolutionary variants in 96% of the samples that were SI in
MT-2 cells. Overall, V3-HTA results predicted the presence or
absence of SI variants in 88% of the samples. The heterodu-
plex patterns showed clonal outgrowth of variants in patient
plasma, which is in agreement with previous observations,
based on the analysis of patient PBMC DNA, that several
distinct populations of virus appear to coexist (30, 34). In our
studies, many of the SI samples had only evolutionary variants
that corresponded to the SI phenotype, which suggests that
NSI variants were either replaced or overgrown by SI variants
in these individuals. In other SI samples, there were several V3
evolutionary variants. In the one case where we examined the
sequence relationships among the multiple variants, some se-
quences appeared to be intermediate to the evolution of others
(sample 300) (Fig. 5A). We reached a similar conclusion in
studying the PBMC DNA of two previous patients (34).
Through the comparison of V3-HTA and sequence analysis,
two conclusions can be made about the physical basis for the
shifts seen in V3-HTA. First, deletions and insertions that
produce shifts in heteroduplex mobility are not necessarily
associated with SI phenotypes and do not necessarily have the
hallmarks of SI genotypes. Deletions of 3 bp resulted in large
heteroduplex shifts in this use of HTA, as is seen when larger
PCR products are used (13). Patient plasma samples 119 and
252 each had a 3-bp deletion that was completely responsible
for the large shift in mobility but apparently did not affect the
phenotype. Second, shifts in heteroduplex mobility do not re-
flect the total number of mismatches in the heteroduplex but
rather the placement of the mismatches. Delwart et al. showed
that heteroduplex mobility is slowed with an increasing per-
centage of mismatches (without deletions) in the heteroduplex
(13). In V3-HTA, however, clustering of at least two mis-
matches no more than 1 bp apart appears to be necessary for
a shift in mobility. The sequences of the two variants from
patient plasma sample 115 showed that a single-substitution
difference was sufficient for a shift in mobility, since that sub-
stitution formed a cluster of three mismatches, spaced 1 bp
apart, in the heteroduplex. Sequences of variants from patient
plasma sample 300 confirmed the clustering effect on hetero-
duplex shifts. Two different clones from sample 300 each had
six substitutions, but the mobilities of the heteroduplexes from
these clones were different. The clone that had two mismatches
that were only 1 bp apart had a shift to lower mobility com-
pared to the clone with an equivalent number of widely spaced
mismatches.
Sequence analysis provided explanations for the discordance
between SI phenotype and the presence of evolutionary V3
variants for six of the patient plasma samples studied. As dis-
cussed above, two of the NSI samples had 3-bp deletions within
their NSI V3 sequences that resulted in heteroduplex shifts in
V3-HTA. The sequence of the PCR product from a third
sample, 115, that was NSI in MT-2 cells showed that this
patient’s virus had evolved away from the NSI consensus but
was not evolving toward an SI phenotype. Because of the wide
variety of V3 sequences that have been identified among indi-
viduals infected with subtype B HIV-1, it is expected that a few
variant V3 sequences (like those from patients 115, 119, and
252) will have sufficient mismatches with the consensus probe
to produce V3-HTA shifts while remaining NSI. For two other
discordant patient samples, 129 and 216, evolutionary variants
were detected by V3-HTA and the sequences of the PCR
products from plasma had changes associated with SI geno-
types but the PBMC-derived virus was NSI. These results sug-
gest that evolution toward SI may be occurring in these indi-
viduals, which would indicate that V3-HTA is able to detect
the development of SI variants prior to their detection in MT-2
cells. Alternatively, these sequences may be different types of
variants that are not evolving toward the SI phenotype. These
variants may still be biologically relevant and may even lead to
rapid progression but fail to score in the MT-2 cell culture
assay. The sequence of the single SI patient sample, 349, that
did not have evolutionary variants in V3-HTA showed no SI-
associated substitutions in V3. Thus, for this variant, the SI
determinants must lie outside of V3. SI determinants have
been identified outside of V3, although usually these determi-
nants are required in addition to V3 substitutions (4, 23).
As described above, V3-HTA measures clustering of mis-
matches in heteroduplexes rather than the total number of
mismatches. This feature of the assay is actually advantageous
for detection of SI variants. The NSI variants in different in-
fected individuals can vary greatly from the NSI consensus
while remaining NSI. Since the scattered mutations typically
seen in these NSI V3 sequences do not cause shifts in hetero-
duplex mobility, few plasma samples will produce a false score
in V3-HTA. On the other hand, SI variants tend to have a
greater amount of variability, especially around positions 19 to
25 (35), which results in clustered mismatches. Therefore, V3-
HTA is especially well suited to the differentiation between
NSI and SI variants.
The sequence analysis of these patient samples with discor-
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dant phenotypes in the two assays indicated that the assays had
different sensitivities. By definition, the MT-2 cell culture assay
is able to detect SI variants, but it is an assay for an in vitro
phenotype. It is not known whether the ability of a variant to
induce syncytia in MT-2 cells is directly related to a biological
consequence of HIV infection. Therefore, it is possible that
people who have rapid disease progression may have variants
that are important in disease but do not cause syncytia in MT-2
cells. V3-HTA, on the other hand, detects variation within V3.
The assay is able to detect variants that may be biologically
relevant in terms of disease course, regardless of their ability to
infect or induce syncytia in MT-2 cells. The assay may also be
able to detect the evolution toward SI before the MT-2 cell
culture assay does, which could be used to identify patients in
whom therapy could possibly prevent SI emergence.
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